News
16h
Zacks Investment Research on MSNCan New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?AbbVie ABBV continues to build momentum with its oncology franchise, with the recent FDA approval for Emrelis. This ...
ELAHERE was approved under FDA's accelerated approval program based on objective response rate (ORR) and duration of response (DOR) data from the pivotal SORAYA trial. Continued approval may be ...
Elahere (mirvetuximab soravtansine-gynx*) is a prescription drug used to treat certain types of cancer, including ovarian cancer. Elahere comes as a liquid solution that’s given as an ...
Elahere is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to a cancer medicine. Elahere is used to treat a ...
Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα ...
Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. As with other drugs, Elahere can cause side effects, such as eye problems ...
ELAHERE® (mirvetuximab soravtansine-gynx) was granted full FDA approval in the United States in March 2024. Marketing authorization submissions for mirvetuximab soravtansine are under review ...
Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. Elahere has interactions with some other drugs. Examples include certain ...
Hosted on MSN8mon
EMA Committee Endorses AbbVie's Elahere in Ovarian CancerIf approved, this will be the first regulatory approval for Elahere in the EU. ABBV Stock Performance Year to date, AbbVie’s shares have moved up 24.9% compared with the industry’s 23.5% rise.
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: Skorzewiak via Shutterstock. The European Commission (EC) has granted marketing ...
Elahere (mirvetuximab soravtansine-gynx) is a prescription drug used to treat certain types of ovarian, fallopian tube, and peritoneal cancer in adults. Elahere can cause side effects that range ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results